News

SNBL announced the results for the quarter ended June 30, 2021.

1. Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2022 (Under Japanese GAAP)
2. Supplementary Material on Quarterly Financial Results 1Q FY202203
3. Notice Regarding Extraordinary Income and Upward Revision of the Earnings Forecasts for the Six Months of the Fiscal Year Ending March 31, 2022

SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19. The role of SNBL is to plan and conduct the preclinical safety studies of the DNA vaccine, which has collaboratively been developed by AnGes, Inc. and Osaka University, in order to conduct the clinical trial as early as possible.   This vaccine uses plasmid DNA technology which means that it can be produced faster than attenuated vaccines. DNA vaccines are safe and work by inoculating a plasmid encoding the protein of the target pathogen.

SNBL's mission is to free patients from suffering, by supporting drug development and improving medical technology, and participation in this project gives SNBL the chance to do so for those suffering from the novel coronavirus.

On April 7, 2020, Japanese Prime Minister Shinzo Abe declared a state of emergency in 7 areas of Japan due to COVID-19, including large cities such as Tokyo and Osaka. This does not apply to the areas in which SNBL's two major laboratories are located.

SNBL has already taken measures to keep our employees safe, such as increasing teleworking and securing supplies. We are doing what we can to keep people safe through research into vaccine and drug therapy safety.

SNBL is dedicated to business continuity while striking a balance with the safety of our employees, clients, and stakeholders. For more information on our business continuity plan, please contact info@snbl.co.jp.